Nivolumab plus ipilimumab and cobimetinib in previously treated microsatellite-stable/DNA mismatch repair-proficient metastatic colorectal cancer: the phase II CheckMate 142 trial

Background: Immune checkpoint inhibitors (ICIs) have shown limited efficacy in patients with microsatellite-stable/DNA mismatch repair-proficient (MSS/pMMR) metastatic colorectal cancer (CRC). Based on data suggesting antitumor synergy between ICIs and MEK inhibitors, the phase II CheckMate 142 tria...

Täydet tiedot

Bibliografiset tiedot

Päätekijät:	M.J. Overman, S. McCraith, B. He, L. Jin, M. Lei, J. Yao, M.A. Morse
Aineistotyyppi:	Artigo
Kieli:	Inglês
Julkaistu:	Elsevier 2026-06-01
Sarja:	ESMO Gastrointestinal Oncology
Aiheet:	nivolumab ipilimumab cobimetinib metastatic colorectal cancer MSS/pMMR
Linkit:	http://www.sciencedirect.com/science/article/pii/S2949819826000348
Tagit:	Lisää tagi Ei tageja, Lisää ensimmäinen tagi!